Company intelligence / Profile preview

Affymax, Inc.

New York, New York, United Statesaffymax.com ↗

Ownership: Public · AFFY
Employees: ~2
Development stage: Phase 1

Overview

Previously developed Omontys, an anemia drug that was recalled in 2013 due to serious hypersensitivity reactions including patient deaths. The drug was not permitted to return to the market, and the company decided to dissolve in 2014[1][4].

Therapeutic areas: Nephrology
Modalities: Small molecules (inferred from combinatorial chemistry background)
Industry: Biotech

Drug pipeline

1 asset

peginesatide

Discontinued

Partnerships

Previously partnered with Takeda (dissolved in 2014)[1]

Financials

Market cap: $60K
Total revenue: $42K
Enterprise value: $-3.3M

Beyond the preview

Go deeper on Affymax, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Affymax, Inc..

Explore the full profile